Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 25,600 | $6.32 | $161,792.00 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,900 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · derivative · entry 14 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,800 Underlying: Common Stock · 3,900 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 2,697 | $29.50 | $79,561.50 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.07 to 29.88, inclusive. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 1,203 | $28.55 | $34,345.65 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,376 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.15 to 28.75, inclusive. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,900 | $6.32 | $24,648.00 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,900 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · derivative · entry 13 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,700 Underlying: Common Stock · 14,900 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 4,988 | $29.58 | $147,545.04 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.03 to 30.02, inclusive. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 7,912 | $28.63 | $226,520.56 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,667 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.03 to 29.01, inclusive. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 2,000 | $27.72 | $55,440.00 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,579 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.43 to 28.01 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 14,900 | $6.32 | $94,168.00 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-20-025388 · doc4.xml · derivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2025-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001209191-20-025388 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $4.07 | $40,700.00 |
DisclosureSEC source: 0001209191-20-025388 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| April 20, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-028687 · doc4a.xml · derivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 740,000 Underlying: Common Stock · 5,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 20, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-20-028687 · doc4a.xml · derivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 5,000 shares Expires 2025-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 20, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001209191-20-028687 · doc4a.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| April 20, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $4.07 | $20,350.00 |
DisclosureSEC source: 0001209191-20-028687 · doc4a.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| April 20, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $6.32 | $31,600.00 |
DisclosureSEC source: 0001209191-20-028687 · doc4a.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,120 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · derivative · entry 14 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,560 Underlying: Common Stock · 11,120 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F9 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 10,620 | $28.34 | $300,970.80 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · nonDerivative · entry 9 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.79 to 28.73, inclusive. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 500 | $27.62 | $13,810.00 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · nonDerivative · entry 8 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,888,800 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.55 to 27.72, inclusive. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 11,120 | $0.33 | $3,669.60 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · nonDerivative · entry 7 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,889,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 33,360 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · derivative · entry 13 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657,680 Underlying: Common Stock · 33,360 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F9 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 33,360 | $28.20 | $940,752.00 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · nonDerivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.78 to 28.45, inclusive. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 33,360 | $0.33 | $11,008.80 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,911,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,560 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · derivative · entry 12 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,040 Underlying: Common Stock · 5,560 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F9 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 3,160 | $26.74 | $84,498.40 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $26.42 to 27.30, inclusive. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 900 | $25.62 | $23,058.00 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,881,340 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $25.34 to 26.11, inclusive. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,500 | $24.83 | $37,245.00 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,882,240 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $24.31 to 25.26, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 5,560 | $0.33 | $1,834.80 |
DisclosureSEC source: 0001209191-20-024558 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,883,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-20-023974 · doc4.xml · derivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 15,000 shares Expires 2025-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 5,300 | $25.07 | $132,871.00 |
DisclosureSEC source: 0001209191-20-023974 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $25.00 to 25.57, inclusive. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 9,700 | $24.14 | $234,158.00 |
DisclosureSEC source: 0001209191-20-023974 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $23.78 to 24.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 15,000 | $4.07 | $61,050.00 |
DisclosureSEC source: 0001209191-20-023974 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| April 08, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-028690 · doc4a.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 745,000 Underlying: Common Stock · 5,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: This transaction was omitted from the reporting person's original Form 4 due to an erroneous trade confirmation. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 08, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-20-028690 · doc4a.xml · derivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 10,000 shares Expires 2025-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 08, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 5,300 | $25.07 | $132,871.00 |
DisclosureSEC source: 0001209191-20-028690 · doc4a.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $25.00 to 25.57, inclusive. Read SEC document |
| April 08, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 9,700 | $24.14 | $234,158.00 |
DisclosureSEC source: 0001209191-20-028690 · doc4a.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $23.78 to 24.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 08, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $4.07 | $40,700.00 |
DisclosureSEC source: 0001209191-20-028690 · doc4a.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| April 08, 2020 Filed May 13, 2020 01:00 UTC Amendment |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $6.32 | $31,600.00 |
DisclosureSEC source: 0001209191-20-028690 · doc4a.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:00 UTC |
ADAMS R MARKChief Technical Officer
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0001209191-20-023973 · doc4.xml · derivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-06 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on April 6, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:00 UTC |
ADAMS R MARKChief Technical Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023973 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 20:30 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,560 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-020638 · doc4.xml · derivative · entry 10 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,600 Underlying: Common Stock · 5,560 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F7 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 20:30 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 887 | $24.38 | $21,625.06 |
DisclosureSEC source: 0001209191-20-020638 · doc4.xml · nonDerivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $24.00 to 24.97, inclusive. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 20:30 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 973 | $23.50 | $22,865.50 |
DisclosureSEC source: 0001209191-20-020638 · doc4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,879,067 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $23.06 to 23.91, inclusive. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 20:30 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 3,700 | $22.37 | $82,769.00 |
DisclosureSEC source: 0001209191-20-020638 · doc4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,880,040 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $22.03 to 22.99, inclusive. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 20:30 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 5,560 | $0.33 | $1,834.80 |
DisclosureSEC source: 0001209191-20-020638 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,883,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:30 UTC |
Palaniappan JyotiSVP, Diagnostics, immunoSEQ Dx
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-20-020640 · doc4.xml · derivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 20:30 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,120 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-020638 · doc4.xml · derivative · entry 9 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,160 Underlying: Common Stock · 11,200 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F7 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 20:30 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 11,120 | $22.30 | $247,976.00 |
DisclosureSEC source: 0001209191-20-020638 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $22.04 to 22.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.